Hinge Health (HNGE) heads into its August 19 appearance at the 5th TestMu Conference, where Head of AI Rashi Agrawal will present, as investors weigh the stock’s recent earnings driven surge and shifting growth profile. See our latest analysis for Hinge Health. At a share price of $88.46, Hinge Health has a 1 day share price return of 0.25% and a 90 day share price return of 60.49%, while the 1 year total shareholder return is 54.54%. This suggests recent momentum has been strongest in the...

Hinge Health stock has delivered a strong year to date gain, yet the current valuation checks point to a share price that screens as expensive on traditional multiples and only a mixed overall value profile. Hinge Health is up 94.2% year to date, which puts extra focus on whether recent optimism is already reflected in the current price. The long term appeal of Hinge Health can depend on the company turning its product reach into sustained revenue growth. Any setback in scaling efficiently...

Hinge Health (NYSE: HNGE) plans to present at the 5th TestMu Conference, with the company’s Head of AI scheduled as a speaker. The appearance focuses on Hinge Health’s use of artificial intelligence in digital musculoskeletal care and broader health tech workflows. The conference slot gives the company a platform to outline its current AI approach to an audience of engineers, product leaders and potential partners. For more ideas in this corner of healthcare and AI, explore the related set...

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

Hinge Health is Wednesday's IBD Stock Of The Day. Shares are consolidating, taking something of a breather, after an earnings-inspired surge.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Jim Cramer fired a triple buy call Aug. 11 on the "Mad Money" Lightning Round. It came for a stock most people still have not heard of. He backed it up with four words that tell you exactly why. Let’s see where he finds that conviction call. [Buy, buy, buy]. What a quarter they had. Hinge ...

On August 4, Hinge Health (NASDAQ:HNGE) delivered a quarter that beat its own guidance on nearly every line, then turned around and used the extra cash to buy its way into a brand new category. Revenue grew 53% year-over-year, margins expanded by roughly 1,000 basis points, and the company still found $105 million to acquire […]

HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.

Investors need to pay close attention to HNGE stock based on the movements in the options market lately.

Yield improvements and member engagement drove 53% revenue growth in the quarter.

IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

Hinge Health (NYSE:HNGE) has agreed to acquire Cylinder Health, a virtual first digestive healthcare company. The deal marks Hinge Health's entry into gastrointestinal care alongside its musculoskeletal and migraine services. The company plans to launch an integrated Gastrointestinal Care Program as part of its broader digital health offering. For investors watching how digital health platforms expand into multi condition care and use data and software to support that shift, it can be...

Hinge Health (HNGE) drew investor attention on 4 August 2026 after reporting second quarter earnings, issuing updated guidance for 2026, and detailing recent share repurchases under its expanded buyback authorization. See our latest analysis for Hinge Health. At a share price of $80.79, Hinge Health has a 1-day share price return of 1.73% and a 7-day share price return of 7.56%, while the 30-day share price return is down 9.53%. Even so, the 90-day share price return of 44.22%, year to date...

Hinge is purchasing Cylinder Health in a “logical extension” of the San Francisco-based company’s business, one analyst commented.

Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.

Moby summary of Hinge Health, Inc.'s Q2 2026 earnings call

Hinge Health (NYSE:HNGE) reported second-quarter 2026 revenue of $213 million, up 53% from a year earlier and above the company’s prior guidance range of $200 million to $202 million. The digital healthcare company also raised its full-year revenue and operating-income outlook, citing durable improv

Hinge Health Inc. (HNGE) delivered earnings and revenue surprises of 0.00% and +6.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.

RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

Hinge Health Inc. (HNGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.

Hinge Health stock has delivered strong 1 year returns, yet the current valuation checks suggest it no longer looks like a clear bargain, with the broader picture pointing to pricing that is closer to fair than obviously cheap. Hinge Health is up 65.8% over the past year, which sets a high bar for further upside if expectations do not keep pace. Expectations for future growth in digital musculoskeletal care can support today’s price, but any slowdown in revenue expansion or the path toward...

IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.